The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib

Itacitinib is a novel, selective, Janus kinase 1 inhibitor in development for treatment of graft‐versus‐host disease. The objective of this study was to assess pharmacokinetics and safety of 300‐mg itacitinib dosed in participants with normal renal function (n = 10), severe renal impairment (n = 8),...

Descripción completa

Detalles Bibliográficos
Autores principales: Srinivas, Nithya, Barbour, April M., Epstein, Noam, Zhou, Gongfu, Petusky, Susan, Xun, Zhinyin, Yuska, Brad, Marbury, Thomas, Chen, Xuejun, Yeleswaram, Swamy, Punwani, Naresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
NON COVID RELATED ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496630/
https://www.ncbi.nlm.nih.gov/pubmed/32149388
http://dx.doi.org/10.1002/jcph.1601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496630/
https://www.ncbi.nlm.nih.gov/pubmed/32149388
http://dx.doi.org/10.1002/jcph.1601

Ejemplares similares